by Tim Griffin | Aug 31, 2026 | Real World Evidence
The Future of Rare Disease Commercialization Won’t Be Defined by Access Alone Biopharmaceutical companies invest years of development, millions of dollars, and extraordinary scientific expertise to bring rare disease therapies to market. Yet many continue to...
